These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 21116050)

  • 1. Plasma amyloid-β as a function of age, level of intellectual disability, and presence of dementia in Down syndrome.
    Head E; Doran E; Nistor M; Hill M; Schmitt FA; Haier RJ; Lott IT
    J Alzheimers Dis; 2011; 23(3):399-409. PubMed ID: 21116050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma beta-amyloid and duration of Alzheimer's disease in adults with Down syndrome.
    Prasher VP; Sajith SG; Mehta P; Zigman WB; Schupf N
    Int J Geriatr Psychiatry; 2010 Feb; 25(2):202-7. PubMed ID: 19513990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum NGAL is Associated with Distinct Plasma Amyloid-β Peptides According to the Clinical Diagnosis of Dementia in Down Syndrome.
    Naudé PJ; Dekker AD; Coppus AM; Vermeiren Y; Eisel UL; van Duijn CM; Van Dam D; De Deyn PP
    J Alzheimers Dis; 2015; 45(3):733-43. PubMed ID: 25613101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated plasma amyloid beta-peptide 1-42 and onset of dementia in adults with Down syndrome.
    Schupf N; Patel B; Silverman W; Zigman WB; Zhong N; Tycko B; Mehta PD; Mayeux R
    Neurosci Lett; 2001 Apr; 301(3):199-203. PubMed ID: 11257432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Change in plasma Aß peptides and onset of dementia in adults with Down syndrome.
    Schupf N; Zigman WB; Tang MX; Pang D; Mayeux R; Mehta P; Silverman W
    Neurology; 2010 Nov; 75(18):1639-44. PubMed ID: 21041786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased amyloid beta protein levels in children and adolescents with Down syndrome.
    Mehta PD; Capone G; Jewell A; Freedland RL
    J Neurol Sci; 2007 Mar; 254(1-2):22-7. PubMed ID: 17275850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The relationship of plasma Abeta levels to dementia in aging individuals with Down syndrome.
    Matsuoka Y; Andrews HF; Becker AG; Gray AJ; Mehta PD; Sano MC; Dalton AJ; Aisen PS
    Alzheimer Dis Assoc Disord; 2009; 23(4):315-8. PubMed ID: 19571732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma amyloid and tau as dementia biomarkers in Down syndrome: Systematic review and meta-analyses.
    Alhajraf F; Ness D; Hye A; Strydom A
    Dev Neurobiol; 2019 Jul; 79(7):684-698. PubMed ID: 31389176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer's disease.
    Startin CM; Ashton NJ; Hamburg S; Hithersay R; Wiseman FK; Mok KY; Hardy J; Lleó A; Lovestone S; Parnetti L; Zetterberg H; Hye A; ; Strydom A
    Alzheimers Res Ther; 2019 Mar; 11(1):26. PubMed ID: 30902060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated plasma beta-amyloid peptide Abeta(42) levels, incident dementia, and mortality in Down syndrome.
    Schupf N; Patel B; Pang D; Zigman WB; Silverman W; Mehta PD; Mayeux R
    Arch Neurol; 2007 Jul; 64(7):1007-13. PubMed ID: 17620492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An inflammatory and trophic disconnect biomarker profile revealed in Down syndrome plasma: Relation to cognitive decline and longitudinal evaluation.
    Iulita MF; Ower A; Barone C; Pentz R; Gubert P; Romano C; Cantarella RA; Elia F; Buono S; Recupero M; Romano C; Castellano S; Bosco P; Di Nuovo S; Drago F; Caraci F; Cuello AC
    Alzheimers Dement; 2016 Nov; 12(11):1132-1148. PubMed ID: 27452424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Composite Scores of Plasma Tau and β-Amyloids Correlate with Dementia in Down Syndrome.
    Fang WQ; Hwu WL; Chien YH; Yang SY; Chieh JJ; Chang LM; Huang AC; Lee NC; Chiu MJ
    ACS Chem Neurosci; 2020 Jan; 11(2):191-196. PubMed ID: 31799825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The relationship of plasma Aβ levels to dementia in aging individuals with mild cognitive impairment.
    Fei M; Jianghua W; Rujuan M; Wei Z; Qian W
    J Neurol Sci; 2011 Jun; 305(1-2):92-6. PubMed ID: 21440911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma amyloid beta protein 1-42 levels are increased in old Down Syndrome but not in young Down Syndrome.
    Mehta PD; Mehta SP; Fedor B; Patrick BA; Emmerling M; Dalton AJ
    Neurosci Lett; 2003 May; 342(3):155-8. PubMed ID: 12757888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generation of Rabbit Monoclonal Antibody to Amyloid-β38 (Aβ38): Increased Plasma Aβ38 Levels in Down Syndrome.
    Mehta PD; Patrick BA; Barshatzky M; Mehta SP; Frackowiak J; Mazur-Kolecka B; Miller DL
    J Alzheimers Dis; 2015; 46(4):1021-32. PubMed ID: 26402629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma β amyloid and the risk of Alzheimer's disease in Down syndrome.
    Coppus AM; Schuur M; Vergeer J; Janssens AC; Oostra BA; Verbeek MM; van Duijn CM
    Neurobiol Aging; 2012 Sep; 33(9):1988-94. PubMed ID: 21958962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gesell Developmental Schedules scores and the relevant factors in children with Down syndrome.
    Yang J; Hu L; Zhang Y; Shi Y; Jiang W; Song C
    J Pediatr Endocrinol Metab; 2020 Apr; 33(4):539-546. PubMed ID: 32242832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults.
    Fagan AM; Roe CM; Xiong C; Mintun MA; Morris JC; Holtzman DM
    Arch Neurol; 2007 Mar; 64(3):343-9. PubMed ID: 17210801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of plasma Aβ as predictor of Alzheimer's disease in older individuals without dementia: a population-based study.
    Hansson O; Stomrud E; Vanmechelen E; Östling S; Gustafson DR; Zetterberg H; Blennow K; Skoog I
    J Alzheimers Dis; 2012; 28(1):231-8. PubMed ID: 21955816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum MHPG strongly predicts conversion to Alzheimer's disease in behaviorally characterized subjects with Down syndrome.
    Dekker AD; Coppus AM; Vermeiren Y; Aerts T; van Duijn CM; Kremer BP; Naudé PJ; Van Dam D; De Deyn PP
    J Alzheimers Dis; 2015; 43(3):871-91. PubMed ID: 25125467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.